# Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

> **NCT03373383** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 411 (actual)

## Conditions studied

- Drug-resistant Epilepsy
- Focal-Onset Seizures

## Interventions

- **DRUG:** Padsevonil
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03373383
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-12
- **Primary completion:** 2020-01-30
- **Final completion:** 2020-01-30
- **Target enrollment:** 411 (ACTUAL)
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03373383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03373383, "Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03373383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*